In this week’s edition of InnovationRx, we look at cheaper biologic drugs, Novo Nordisk’s $2 billion next-gen obesity drug deal, new ways of fighting cancer, and more.

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from unwanted side effects and limited efficacy. In a recent Bioconjugate ...

Astellas Pharma has agreed to co-develop and co-commercialize Vir Biotechnology’s prostate cancer candidate VIR-5500 through a collaboration that could generate more than $1.7 billion for the San ...

As is often the case with cancer treatments, many patients are able to benefit from therapy for a time. Tumor activity ...

Many breast cancer drugs block estrogen receptors inside cancer cells. Blocking the receptors early in disease progression staves off metastasis. But most patients with advanced disease eventually ...

Rare Disease Day is held on the last day of February to raise awareness for rare diseases and address drug development ...

FDA fast track covers ART6043 plus olaparib in PARP inhibitor–naïve gBRCAm, HER2-negative locally advanced/metastatic breast ...

When cancer-driving proteins resist various treatments, Northwestern University scientists have uncovered a new solution. Don ...

CEOCFO interviews NanOlogy, LLC CEO David J. Arthur on Solving Toxicity & Bioavailability Problems when Treating ...

CAMBRIDGE, England--(BUSINESS WIRE)--Crescendo Biologics Ltd (Crescendo), the developer of novel, targeted, T cell enhancing therapeutics, and Cancer Research UK, the world’s largest independent ...

Advances in cancer research have led to an increasing number and variety of cancer therapies in the development pipeline, but there are concerns that traditional processes for drug development, ...